Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 2 | 6 | 8 |
| 2012 | 2 | 4 | 6 |
| 2013 | 4 | 1 | 5 |
| 2014 | 7 | 8 | 15 |
| 2015 | 2 | 4 | 6 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 6 | 9 |
| 2018 | 3 | 6 | 9 |
| 2019 | 8 | 2 | 10 |
| 2020 | 7 | 3 | 10 |
| 2021 | 3 | 5 | 8 |
| 2022 | 2 | 5 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clin Cancer Res. 2022 09 15; 28(18):3950-3957.
-
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022 08 23; 6(16):4736-4739.
-
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials. Clin Exp Allergy. 2022 09; 52(9):1105-1109.
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
-
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
-
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. Am J Med. 2022 07; 135(7):915-918.
-
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022 05; 149(5):1711-1721.e6.
-
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 01; 74(1):112-123.
-
Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis. Inflamm Bowel Dis. 2021 Nov 15; 27(12):e147.
-
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021 12; 22(12):1777-1786.